drugset / Trial / NCT07604571
Study of IEV407 as Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer
RandomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety, tolerability and preliminary activity of IEV407 as a single agent and in combination with endocrine therapy (fulvestrant or letrozole) in patients with advanced hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer.
Timeline
- Start
- 2026-05-28
- Primary completion
- 2032-06-08
- Completion
- 2032-06-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | — | Intramuscular |
| Subject | IEV407 | Unknown | — | Oral |
| Subject | Letrozole | Other / unclassified | — | Oral |